XORTX Therapeutics Inc (XRTX)

NASDAQ: XRTX · IEX Real-Time Price · USD
0.880
+0.019 (2.18%)
Dec 7, 2022 3:54 PM EST - Market closed
2.18%
Market Cap 14.10M
Revenue (ttm) n/a
Net Income (ttm) 2.53M
Shares Out 12.99M
EPS (ttm) 0.35
PE Ratio 2.51
Forward PE 0.96
Dividend n/a
Ex-Dividend Date n/a
Volume 6,156
Open 0.861
Previous Close 0.861
Day's Range 0.861 - 0.925
52-Week Range 0.663 - 2.61
Beta 0.31
Analysts Buy
Price Target 6.94 (+688.5%)
Earnings Date Nov 25, 2022

About XRTX

XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and X... [Read more]

Industry Biotechnology
Founded 2011
CEO Allen Davidoff
Employees 2,021
Stock Exchange NASDAQ
Ticker Symbol XRTX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for XRTX stock is "Buy." The 12-month stock price forecast is 6.94, which is an increase of 688.55% from the latest price.

Price Target
$6.94
(688.55% upside)
Analyst Consensus: Buy
Stock Forecasts

News

XORTX Announces Completion of Screening and Enrollment in Bridging Pharmacokinetics Study

XRX-OXY-101 Study will inform the dose choice in the upcoming Phase 3 Clinical Trial XRX-OXY-101 Study will inform the dose choice in the upcoming Phase 3 Clinical Trial

1 week ago - GlobeNewsWire

XORTX Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

CALGARY, Alberta, Nov. 25, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused ...

1 week ago - GlobeNewsWire

XORTX Therapeutics Appoints Stacy Evans, M.D., MBA as Chief Business Officer

Dr. Evans brings extensive strategic experience to advance search for XRx-008 Phase 3 development and commercialization partner Dr. Evans brings extensive strategic experience to advance search for XRx-...

3 weeks ago - GlobeNewsWire

XORTX Presents New Proof of Concept Data at American Society of Nephrology

● Xanthine Oxidase Inhibition with XRx-008 Blocks Uric Acid Induced Increase in Total Kidney Weight in Polycystic Kidney Disease ●

1 month ago - GlobeNewsWire

XORTX Announces Participation at Upcoming Investor Conferences

CALGARY, Alberta, Nov. 03, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused ...

1 month ago - GlobeNewsWire

XORTX Announces Closing of US$5 Million Public Offering

CALGARY, Alberta, Oct. 07, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused ...

2 months ago - GlobeNewsWire

XORTX Announces US$5 Million Public Offering

CALGARY, Alberta, Oct. 04, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused ...

2 months ago - GlobeNewsWire

XORTX Completes Positive Pre-Phase 3 Meeting with the US Food and Drug Administration

CALGARY, Alberta, Sept. 19, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a clinical development stage pharmaceutical company ...

2 months ago - GlobeNewsWire

Why Is Xortx Therapeutics (XRTX) Stock Moving Today?

Source: Bukhta Yurii / Shutterstock.com Xortx Therapeutics (NASDAQ: XRTX ) stock is moving on Monday after the company reported positive results from a clinical trial. Those results come from the second...

3 months ago - InvestorPlace

XORTX Announces Positive Topline Results from Part 2 Pharmacokinetics Bridging Study

Clinical Trial Shows Substantially Increased Bioavailability with Food and a Clean Safety and Pharmacologic Profile Clinical Trial Shows Substantially Increased Bioavailability with Food and a Clean Saf...

3 months ago - GlobeNewsWire

XORTX Reports Annual & Special Meeting Results

CALGARY, Alberta, July 22, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused ...

4 months ago - GlobeNewsWire

XORTX Announces Submission to European Medicines Agency

Scientific Advice from EMA Committee for Medicinal Products for Human Use Requested Scientific Advice from EMA Committee for Medicinal Products for Human Use Requested

4 months ago - GlobeNewsWire

Why Are XORTX Therapeutics Shares Skyrocketing Today?

XORTX Therapeutics Inc (NASDAQ: XRTX) has announced topline results from Part 1 of the three-part Pharmacokinetics Bridging Study – XRX-OXY-101. The data showed a substantial increase in oral bioavailab...

4 months ago - Benzinga

XORTX Announces Positive Topline Results from Pharmacokinetics Bridging Clinical Trial

Clinical Trial Shows Substantially Improved Bioavailiability Clinical Trial Shows Substantially Improved Bioavailiability

4 months ago - GlobeNewsWire

XORTX Announces Pre-Phase 3 Meeting Request with US Food and Drug Administration (FDA)

CALGARY, Alberta, July 07, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused ...

5 months ago - GlobeNewsWire

XORTX to Present at BIO International Convention 2022

CALGARY, Alberta, June 13, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused ...

5 months ago - GlobeNewsWire

XORTX Welcomes New Member to the Board of Directors and Appoints Chair

CALGARY, Alberta, June 06, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused ...

6 months ago - GlobeNewsWire

XORTX Receives Small and Medium Enterprise Status for the European Union

CALGARY, Alberta, April 20, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a pharmaceutical company focused on developing innov...

7 months ago - GlobeNewsWire

XORTX Receives No Objection Letter from Health Canada

Bridging Pharmacokinetics Study Autosomal Dominant Polycystic Kidney Disease – XRx-008 Program Bridging Pharmacokinetics Study Autosomal Dominant Polycystic Kidney Disease – XRx-008 Program

7 months ago - GlobeNewsWire

XORTX Announces Grant of US Patent

Patent supporting Autosomal Dominant Polycystic Kidney Disease Granted – XRx-008 Program Patent supporting Autosomal Dominant Polycystic Kidney Disease Granted – XRx-008 Program

8 months ago - GlobeNewsWire

XORTX Files IND with US FDA

● Autosomal Dominant Polycystic  Kidney Disease – XRx-008 Program IND Filed ●

8 months ago - GlobeNewsWire

Here's Why XORTX Therapeutics Shares Are Rising

XORTX Therapeutics (NASDAQ: XRTX) shares are trading higher by 54.6% at $1.87 after the company announced the submission of a Patent Cooperation Treaty patent application seeking international patent pr...

8 months ago - Benzinga

XORTX Files New PCT Patent to Treat and Protect Individuals Most at Risk to Severe Viral Infection

Compositions and Methods for Enhancing Anti-Viral Therapies Compositions and Methods for Enhancing Anti-Viral Therapies

8 months ago - GlobeNewsWire

XORTX Therapeutics Announces Submission of Clinical Trial Application to Conduct Bridging Pharmacokinetics Study

Bridging Pharmacokinetic Study Initiated Bridging Pharmacokinetic Study Initiated

8 months ago - GlobeNewsWire

XORTX Provides Corporate Update

Synopsis of 2021 Achievements and Key Activities for 2022 Synopsis of 2021 Achievements and Key Activities for 2022

10 months ago - GlobeNewsWire